- Previous Close
160.00 - Open
167.00 - Bid 164.00 x 3000
- Ask 165.00 x 34000
- Day's Range
162.00 - 167.00 - 52 Week Range
130.00 - 203.00 - Volume
5,245 - Avg. Volume
22,596 - Market Cap (intraday)
2.977B - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
28.80 - EPS (TTM)
5.66 - Earnings Date May 9, 2025
- Forward Dividend & Yield 4.50 (2.81%)
- Ex-Dividend Date Apr 25, 2024
- 1y Target Est
172.00
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
www.medistim.comRecent News: MEDI.OL
View MorePerformance Overview: MEDI.OL
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDI.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDI.OL
View MoreValuation Measures
Market Cap
2.92B
Enterprise Value
2.77B
Trailing P/E
28.22
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.21
Price/Book (mrq)
6.69
Enterprise Value/Revenue
4.92
Enterprise Value/EBITDA
17.38
Financial Highlights
Profitability and Income Statement
Profit Margin
18.67%
Return on Assets (ttm)
15.16%
Return on Equity (ttm)
24.88%
Revenue (ttm)
556.16M
Net Income Avi to Common (ttm)
103.83M
Diluted EPS (ttm)
5.66
Balance Sheet and Cash Flow
Total Cash (mrq)
179.21M
Total Debt/Equity (mrq)
7.87%
Levered Free Cash Flow (ttm)
81.67M